|
Apr 26
|
Bristol-Myers Squibb First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Apr 24
|
Bristol Myers Squibb Reverses Its Losing Spree On First-Quarter Beat
|
|
Apr 24
|
Bristol-Myers Squibb (NYSE:BMY) Raises 2025 Revenue Guidance Following Strong Q1 Performance
|
|
Apr 24
|
Netflix's new high, Bristol Myers outlook, Texas Instruments pops
|
|
Apr 24
|
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
|
|
Apr 22
|
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
|
|
Apr 22
|
Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test
|
|
Apr 22
|
Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)
|
|
Feb 16
|
New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
|
|
Feb 13
|
Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
|
|
Feb 12
|
Shareholders in Bristol-Myers Squibb (NYSE:BMY) have lost 7.2%, as stock drops 5.4% this past week
|
|
Feb 11
|
The Magnificent 7 Are So Last Year. Cash Cows Are the New Kings.
|
|
Feb 10
|
Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
|
|
Jan 3
|
Bristol Myers Squibb to Present at J.P. Morgan’s 43rd Annual Healthcare Conference
|
|
Jan 2
|
Bristol-Myers Squibb's (NYSE:BMY) investors will be pleased with their 2.4% return over the last five years
|
|
Oct 3
|
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
|
|
Oct 3
|
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
|
|
Oct 1
|
Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
|
|
Sep 30
|
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
|
|
Sep 27
|
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
|